About BBM | Belief Biomed Inc

Company Introduction

Founded in 2018, Belief BioMed is aiming to become a globally leading gene therapy company by being committed to providing innovative therapies with improved efficacy for monogenic disorder diseases, age-related degenerative diseases, and certain malignant diseases through its AAV vector technology from early discovery to commercialization. The R&D and production strengths of Belief BioMed have been recognized by top investment institutions and enterprises. Belief BioMed has offices, research centers and manufacturing facilities in Shanghai, Hong Kong, Beijing and Suzhou China and North Carolina US.

Mission And Vision

Our Mission

Make gene therapy drugs available, affordable and healable.

Our Vision

To become the pioneer leading China’s gene therapy industry, to bring China’s gene therapy drugs to the world.

Key Milestones

2016

Belief BioMed core team set up

2017

High productivity cell line established

2018

CMC research and development center established, the production of hemophilia B IIT drug is completed

2019

Experimental Rodent Animal Center officially put into use, hemophilia B IIT officially launched, drug administration in primates Parkinson’s disease model, and 50L process put into production

2020

The Shanghai office, as the global headquarter and clinical research development center, officially opened; the 5,000m ² production and research base officially opened (Shanghai Minhang Science and Technology Park of ECUST); the 300m² non-human primate experiment center officially opened; hemophilia B submitted pre-IND to NMPA CDE; and two MNC License out contracts were signed; One year’s data from primate model of Parkinson’s disease; 200L manufacturing process was locked down and applied in the batch production.

2021

On May 14, 2021, BBM-H901as the first Hemophilia gene therapy drug and the first AAV IND gene therapy drug for rare disease intravenous administration in China, was successfully submitted and accepted by NMPA CDE. The construction of 15,000m ² commercial production and manufacturing center officially started (Shanghai Harbor Free Trade Zone Intelligent Manufacturing Park), and the 500L process put into operation.
On August 6, 2021, BBM-H901 injection (AAV gene therapy drug used to prevent haemophilia B in adult male patients) , was approved by National Medical Products Administration (NMPA) to enter the registered clinical trial stage.
On November, a subsidiary of Belief BioMed, also won the approval of special funds for the development of strategic emerging industries in Shanghai.
On December, Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B.

2022

On May, Clinical results for Belief BioMed’s developing hemophilia B gene treatment BBM-H901 published in authoritative hematology journal The Lancet Haematology.